PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23043158-7	2013	Fenofibrate also attenuated overexpression of intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and vascular endothelial growth factor (VEGF) and blocked activation of hypoxia-inducible factor-1 and nuclear factor-kappaB in the retinas of OIR and diabetic models.	Fenofibrate	0-11	C-C motif chemokine ligand 2	Homo sapiens	81-115	
31708994-9	2019	Treatment of senescent SF with the senolytic drug fenofibrate normalized IL6, CXCL8 and CCL2 mRNA expression.	Fenofibrate	50-61	C-C motif chemokine ligand 2	Homo sapiens	88-92	
26617775-4	2015	We observed in HK-2 cells that fenofibrate significantly inhibited fatty acids bound albumin (FA-BSA) induced up-regulation of MCP-1 and IL-8.	Fenofibrate	31-42	C-C motif chemokine ligand 2	Homo sapiens	127-132	
26136131-5	2015	Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups.	Fenofibrate	13-24	C-C motif chemokine ligand 2	Homo sapiens	150-155	
26136131-5	2015	Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups.	Fenofibrate	42-53	C-C motif chemokine ligand 2	Homo sapiens	150-155	
26136131-7	2015	The effect of simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 and MCP-1 was more pronounced in the male population.	Fenofibrate	26-37	C-C motif chemokine ligand 2	Homo sapiens	99-104	
22228203-7	2012	Associations of the MCP1-TNF-alpha pattern with loci in several biologically plausible genes [CYP4F8 (rs3764563), APBB1IP (rs1775246), COL13A1 (rs2683572), and COMMD10 (rs1396485)] approached genome-wide significance (P=3x10, 5x10, 6x10, and 7x10, respectively) before fenofibrate treatment.	Fenofibrate	269-280	C-C motif chemokine ligand 2	Homo sapiens	20-24	
22228203-8	2012	After fenofibrate treatment, the rs12722605 locus in IL2RA was also associated with the MCP1-TNF-alpha pattern (P=3x10).	Fenofibrate	6-17	C-C motif chemokine ligand 2	Homo sapiens	88-92	
21276586-5	2011	Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels.	Fenofibrate	16-27	C-C motif chemokine ligand 2	Homo sapiens	125-159	
16600694-5	2006	The results showed that (i) aspirin, fenofibrate and clofibrate decrease significantly the MCP-1 expression and secretion in human endothelial cells; (ii) the high glucose up-regulated expression of MCP-1 in endothelial cells was significantly reduced by inhibitors of NF-kB and reactive oxygen species; (iii) all drugs notably decrease the level of the reactive oxygen species and activation of NF-kB and AP-1.	Fenofibrate	37-48	C-C motif chemokine ligand 2	Homo sapiens	91-96	
19132243-7	2008	Treatment of HG-exposed SMC with peroxisome proliferator-activated receptors alpha (PPARalpha) activators (fenofibrate and clofibrate) resulted in a reduction of mRNA and protein expression of MCP-1 and fractalkine.	Fenofibrate	107-118	C-C motif chemokine ligand 2	Homo sapiens	193-214	
20360622-6	2010	In all groups of dyslipidemic patients, micronized fenofibrate reduced monocyte release of interleukin-1beta and MCP-1, and this effect was stronger in prediabetic subjects.	Fenofibrate	51-62	C-C motif chemokine ligand 2	Homo sapiens	113-118	
19825152-8	2009	For both rs12255372 and rs7903146, homozygote T-allele carriers had significantly higher (P < 0.05) post-fenofibrate concentrations of MCP-1 in the recessive model.	Fenofibrate	108-119	C-C motif chemokine ligand 2	Homo sapiens	138-143	
17631136-8	2007	Fenofibrate also repressed the expression of the genes encoding 3 chemokines, CXCL10, CCL2, and CCL20, and repressed CXCL10 gene promoter activity in tumor necrosis factor-alpha-treated HT-29 cells.	Fenofibrate	0-11	C-C motif chemokine ligand 2	Homo sapiens	86-90	
11382718-8	2001	The peroxisome proliferator-activated receptor-alpha activators fenofibrate (100 micromol/L) and Wy-14649 (100 micromol/L) almost completely abolished the induction of MCP-1, but the peroxisome proliferator-activated receptor-gamma activator ciglitazone had only a moderate effect.	Fenofibrate	64-75	C-C motif chemokine ligand 2	Homo sapiens	168-173	
12756509-0	2003	Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.	Fenofibrate	42-53	C-C motif chemokine ligand 2	Homo sapiens	65-99	
12756509-2	2003	The aim of this study was to evaluate the secretion of monocyte chemoattractant protein-1 (MCP-1) by monocytes from hyperlipidemic patients treated with hypolipidemic drugs, namely fenofibrate, simvastatin, or atorvastatin to determine what role is played by these drugs in the development and stabilization of the atherosclerotic plaque.	Fenofibrate	181-192	C-C motif chemokine ligand 2	Homo sapiens	55-89	
12756509-11	2003	Fenofibrate, atorvastatin, and simvastatin significantly decreased MCP-1 levels from 15.8+/-0.47 to 8.79+/-0.89, from 16.7+/-0.23 to 7.46+/-0.73, and from 14.9+/-0.45 to 10.3+/-0.8 ng/ml, respectively.	Fenofibrate	0-11	C-C motif chemokine ligand 2	Homo sapiens	67-72	
15985720-3	2005	The aim of our study was to assess the effect of fenofibrate, a commonly used hypolipidemic drug, on the release of interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) by monocytes from patients with combined hyperlipidemia.	Fenofibrate	49-60	C-C motif chemokine ligand 2	Homo sapiens	171-205	
15985720-3	2005	The aim of our study was to assess the effect of fenofibrate, a commonly used hypolipidemic drug, on the release of interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) by monocytes from patients with combined hyperlipidemia.	Fenofibrate	49-60	C-C motif chemokine ligand 2	Homo sapiens	207-212	
15985720-10	2005	Thirty-day fenofibrate treatment decreased the release of IL-1beta by 43% (143.9 +/- 6.5 vs. 86.2 +/- 5.9 pg/ml), of IL-6 by 22% (8212 +/- 285 vs. 6330 +/- 234 pg/ml), and of MCP-1 by 29% (19.6 +/- 0.9 vs. 14.0 +/- 0.8 ng/ml).	Fenofibrate	11-22	C-C motif chemokine ligand 2	Homo sapiens	175-180	
15772519-0	2005	Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.	Fenofibrate	35-46	C-C motif chemokine ligand 2	Homo sapiens	60-94	
15772519-9	2005	Our results suggest that atorvastatin and fenofibrate produce their antiinflammatory effect partially via inhibiting monocyte release of MCP-1.	Fenofibrate	42-53	C-C motif chemokine ligand 2	Homo sapiens	137-142	
12816176-0	2003	Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia.	Fenofibrate	11-22	C-C motif chemokine ligand 2	Homo sapiens	61-66	
12816176-10	2003	Fenofibrate (200 mg daily) significantly decreased sICAM-1 (by 17%) and MCP-1 levels (by 12.5%).	Fenofibrate	0-11	C-C motif chemokine ligand 2	Homo sapiens	72-77